Advisors Asset Management, Inc. Nektar Therapeutics Transaction History

Advisors Asset Management, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 15, 2020	SELL	$14.47 - $27.96 $20,619 - $39,843	-1,425 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$15.87 - $23.12 $22,186 - $32,321	-1,398 Reduced 49.52%	1,425 $31,000
Q3 2019 Nov 14, 2019	SELL	$16.91 - $36.27 $16,791 - $36,016	-993 Reduced 26.02%	2,823 $51,000
Q2 2019 Aug 14, 2019	SELL	$31.0 - $36.3 $2,356 - $2,758	-76 Reduced 1.95%	3,816 $136,000
Q1 2019 May 15, 2019	SELL	$31.58 - $46.35 $3,631 - $5,330	-115 Reduced 2.87%	3,892 $131,000
Q4 2018 Jan 31, 2019	SELL	$30.43 - $56.65 $172,325 - $320,808	-5,663 Reduced 58.56%	4,007 $132,000
Q3 2018 Nov 15, 2018	BUY	$46.46 - $68.49 $94,639 - $139,514	2,037 Added 26.69%	9,670 $589,000
Q2 2018 Aug 22, 2018	SELL	$46.25 - $104.45 $30.7 Million - $69.3 Million	-663,441 Reduced 98.86%	7,633 $373,000
Q2 2018 Aug 15, 2018	BUY	$46.25 - $104.45 $31 Million - $70.1 Million	671,074 New	671,074 $373,000

145

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $174M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Advisors Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisors Asset Management, Inc. with notifications on news.